Soligenix
Biotechnology, 29 Emmons Dr Ste B10, Princeton, New Jersey, 08540, United States, 11-50 Employees
Phone Number: 60********
Who is SOLIGENIX
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTher...
Read More
-
Headquarters: 29 Emmons Dr Ste B10, Princeton, New Jersey, 08540, United States
-
Date Founded: 1987
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Soligenix Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Soligenix
Answer: Soligenix's headquarters are located at 29 Emmons Dr Ste B10, Princeton, New Jersey, 08540, United States
Answer: Soligenix's phone number is 60********
Answer: Soligenix's official website is https://soligenix.com
Answer: Soligenix's revenue is $1 Million to $5 Million
Answer: Soligenix's SIC: 2834
Answer: Soligenix's NAICS: 325412
Answer: Soligenix has 11-50 employees
Answer: Soligenix is in Biotechnology
Answer: Soligenix contact info: Phone number: 60******** Website: https://soligenix.com
Answer: Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and commercializing HyBryteTM (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVaxTM). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax. We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month